Email Alert RSS
Volume 12 Issue 6
Nov.  2021
Turn off MathJax
Article Contents
Abstract
References
Related Articles
Gynecological Oncology Society of Chinese Medical Association. Clinical Practice Guidelines on Platinum Therapy in Gynecological Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 881-901. DOI: 10.12290/xhyxzz.2021-0690
Citation: Gynecological Oncology Society of Chinese Medical Association. Clinical Practice Guidelines on Platinum Therapy in Gynecological Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 881-901. DOI: 10.12290/xhyxzz.2021-0690
shu

Clinical Practice Guidelines on Platinum Therapy in Gynecological Tumors

More Information

  • Corresponding authors: KONG Beihua1, LIU Jihong2, XIE Xing3, MA Ding4.
    1. Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Jinan 250012, China, E-mail: kongbeihua@sdu.edu.cn
    2. Department of Gynecologic Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China, E-mail: liujh@sysucc.org.cn
    3. Women's Hopital, School of Medicine Zhejiang University, Hangzhou 310006, China, E-mail: xiex@zju.edu.cn
    4. Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology, Wuhan 430030, China, E-mail: dma@tjh.tjmu.edu.cn

  • Received Date: October 11, 2021
  • Accepted Date: October 12, 2021
  • Available Online: October 24, 2021
  • Issue Publish Date: November 29, 2021
    Graphical Abstract
    • Abstract
  • Platinum drugs have a wide spectrum of activity and remarkable therapeutic effects. Platinum-based chemotherapy is a widely recommended regimen for gynecology oncology. Carboplatin/paclitaxel is the "standard" combination of the first choice of therapy for patients with ovarian cancer. Cisplatin is preferred for cervical cancer. Preventing and mitigating adverse events and drug reactions are an important part of platinum treatment. For platinum-resistant disease, non-platinum-based agents or regimens are preferred. Platinum resistance remains an urgent challenge for the treatment of gynecological tumors. In order to standardize the clinical management of platinum therapy, we organized experts and scholars to discuss many times, and finally formed this consensus.
    • FullText(HTML)
    • References (137)
  • [1]
    Makovec T. Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemo-therapy[J]. Radiol Oncol, 2019, 53: 148-158. DOI: 10.2478/raon-2019-0018
    [2]
    Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage Ⅰ B cervical carcinoma[J]. N Engl J Med, 1999, 340: 1154-1161. DOI: 10.1056/NEJM199904153401503
    [3]
    Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer[J]. N Engl J Med, 1999, 340: 1137-1143. DOI: 10.1056/NEJM199904153401501
    [4]
    Peters WA 3rd, Liu PY, Barrett RJ 2nd, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix[J]. J Clin Oncol, 2000, 18: 1606-1613. DOI: 10.1200/JCO.2000.18.8.1606
    [5]
    Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage Ⅱ B-Ⅳ A carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study[J]. J Clin Oncol, 1999, 17: 1339-1348. DOI: 10.1200/JCO.1999.17.5.1339
    [6]
    Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer[J]. N Engl J Med, 1999, 340: 1144-1153. DOI: 10.1056/NEJM199904153401502
    [7]
    Kim YS, Shin SS, Nam JH, et al. Prospective randomized comparison of monthly fluorouracil and cisplatin versus weekly cisplatin concurrent with pelvic radiotherapy and high-dose rate brachytherapy for locally advanced cervical cancer[J]. Gynecol Oncol, 2008, 108: 195-200. DOI: 10.1016/j.ygyno.2007.09.022
    [8]
    Higgins RV, Naumann WR, Hall JB, et al. Concurrent carboplatin with pelvic radiation therapy in the primary treat-ment of cervix cancer[J]. Gynecol Oncol, 2003, 89: 499-503. DOI: 10.1016/S0090-8258(03)00151-3
    [9]
    Gupta S, Maheshwari A, Parab P, et al. Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage ⅠB2, ⅡA, or ⅡB Squamous Cervical Cancer: A Randomized Controlled Trial[J]. J Clin Oncol, 2018, 36: 1548-1555. DOI: 10.1200/JCO.2017.75.9985
    [10]
    Greggi S, Kenter G, Vergote I, et al. Results from neoadjuvant chemotherapy followed by surgery compared to chemoradiation for StageⅠ B2-Ⅱ B cervical cancer: EORTC55994[J]. Int J Gynecol Cancer, 2019, 29: A12. DOI: 10.1136/ijgc-2019-000666
    [11]
    Sehouli J, Runnebaum IB, Fotopoulou C, et al. A randomized phase Ⅲ adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study[J]. Ann Oncol, 2012, 23: 2259-2264. DOI: 10.1093/annonc/mdr628
    [12]
    Huang H, Feng Y, Wan T, et al. Sequential chemoradiation versus radiation alone or concurrent chemoradiation in adjuvant treatment after radical hysterectomy for stage Ⅰ B1-Ⅱ A2 cervical cancer (STARS Study): A randomized, controlled, openlabel, phase Ⅲ trial[C]. American Society of Clinical Oncology, 2020.
    [13]
    Hosaka M, Watari H, Takeda M, et al. Treatment of cervical cancer with adjuvant chemotherapy versus adjuvant radiotherapy after radical hysterectomy and systematic lymph-adenectomy[J]. J Obstet Gynaecol Res, 2008, 34: 552-556. DOI: 10.1111/j.1447-0756.2008.00739.x
    [14]
    Lee KB, Lee JM, Ki KD, et al. Comparison of adjuvant chemotherapy and radiation in patients with intermediate risk factors after radical surgery in FIGO stageⅠ B-Ⅱ A cervical cancer[J]. Int J Gynecol Cancer, 2008, 18: 1027-1031. DOI: 10.1111/j.1525-1438.2007.01136.x
    [15]
    Takeshima N, Umayahara K, Fujiwara K, et al. Treatment results of adjuvant chemotherapy after radical hysterectomy for intermediate- and high-risk stage Ⅰ B-Ⅱ A cervical cancer[J]. Gynecol Oncol, 2006, 103: 618-622. DOI: 10.1016/j.ygyno.2006.04.019
    [16]
    Weng D, Wang H, Zhu C, et al. Randomized trial of adjuvant chemotherapy versus concurrent chemoradiotherapy in early-stage cervical cancer after radical surgery: A Chinese Gynecologic Oncology Group study (CSEM-002)[J]. Gynecol Oncol, 2018, 149: 30. DOI: 10.1016/j.ygyno.2018.04.070
    [17]
    Moore DH, Blessing JA, McQuellon RP, et al. Phase Ⅲ study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study[J]. J Clin Oncol, 2004, 22: 3113-3119. DOI: 10.1200/JCO.2004.04.170
    [18]
    Long HJ 3rd, Bundy BN, Grendys EC Jr, et al. Randomized phase Ⅲ trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study[J]. J Clin Oncol, 2005, 23: 4626-4633. DOI: 10.1200/JCO.2005.10.021
    [19]
    Monk BJ, Sill MW, McMeekin DS, et al. Phase Ⅲ trial of four cisplatin-containing doublet combinations in stage ⅣB, recurrent, or persistent cervical carcinoma: a Gynecolo-gic Oncology Group study[J]. J Clin Oncol, 2009, 27: 4649-4655. DOI: 10.1200/JCO.2009.21.8909
    [20]
    Kitagawa R, Katsumata N, Shibata T, et al. Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase Ⅲ Trial JCOG0505[J]. J Clin Oncol, 2015, 33: 2129-2135. DOI: 10.1200/JCO.2014.58.4391
    [21]
    Tewari KS, Sill MW, Long HJ 3rd, et al. Improved survival with bevacizumab in advanced cervical cancer[J]. N Engl J Med, 2014, 370: 734-743. DOI: 10.1056/NEJMoa1309748
    [22]
    Takekuma M, Hirashima Y, Ito K, et al. Phase Ⅱ trial of paclitaxel and nedaplatin in patients with advanced/recurrent uterine cervical cancer: a Kansai Clinical Oncology Group study[J]. Gynecol Oncol, 2012, 126: 341-345. DOI: 10.1016/j.ygyno.2012.05.010
    [23]
    Li Y, Zeng J, Huang M, et al. A phase 2 study of nanoparticle albumin-bound paclitaxel plus nedaplatin for patients with advanced, recurrent, or metastatic cervical carcinoma[J]. Cancer, 2017, 123: 420-425. DOI: 10.1002/cncr.30328
    [24]
    Kuo DY, Blank SV, Christos PJ, et al. Paclitaxel plus oxaliplatin for recurrent or metastatic cervical cancer: a New York Cancer Consortium Study[J]. Gynecol Oncol, 2010, 116: 442-446. DOI: 10.1016/j.ygyno.2009.10.082
    [25]
    Gardner GJ, Reidy-Lagunes D, Gehrig PA. Neuroendocrine tumors of the gynecologic tract: A Society of Gynecologic Oncology (SGO) clinical document[J]. Gynecol Oncol, 2011, 122: 190-198. DOI: 10.1016/j.ygyno.2011.04.011
    [26]
    Wang KL, Chang TC, Jung SM, et al. Primary treatment and prognostic factors of small cell neuroendocrine carcinoma of the uterine cervix: a Taiwanese Gynecologic Oncology Group study[J]. Eur J Cancer, 2012, 48: 1484-1494. DOI: 10.1016/j.ejca.2011.12.014
    [27]
    Kuji S, Hirashima Y, Nakayama H, et al. Diagnosis, clinicopathologic features, treatment, and prognosis of small cell carcinoma of the uterine cervix; Kansai Clinical Oncology Group/Intergroup study in Japan[J]. Gynecol Oncol, 2013, 129: 522-527. DOI: 10.1016/j.ygyno.2013.02.025
    [28]
    Boruta DM 2nd, Schorge JO, Duska LA, et al. Multimodality therapy in early-stage neuroendocrine carcinoma of the uterine cervix[J]. Gynecol Oncol, 2001, 81: 82-87. DOI: 10.1006/gyno.2000.6118
    [29]
    Zivanovic O, Leitao MM Jr, Park KJ, et al. Small cell neuroendocrine carcinoma of the cervix: Analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy[J]. Gynecol Oncol, 2009, 112: 590-593. DOI: 10.1016/j.ygyno.2008.11.010
    [30]
    Tempfer CB, Tischoff I, Dogan A, et al. Neuroendocrine carcinoma of the cervix: a systematic review of the literature[J]. BMC Cancer, 2018, 18: 530. DOI: 10.1186/s12885-018-4447-x
    [31]
    Nagao S, Miwa M, Maeda N, et al. Clinical Features of Neuroendocrine Carcinoma of the Uterine Cervix: A Single-Institution Retrospective Review[J]. Int J Gynecol Cancer, 2015, 25: 1300-1305. DOI: 10.1097/IGC.0000000000000495
    [32]
    Faivre-Finn C, Snee M, Ashcroft L, et al. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial[J]. Lancet Oncol, 2017, 18: 1116-1125. DOI: 10.1016/S1470-2045(17)30318-2
    [33]
    Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide[J]. N Engl J Med, 1999, 340: 265-271. DOI: 10.1056/NEJM199901283400403
    [34]
    Skarlos DV, Samantas E, Briassoulis E, et al. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase Ⅱ study of the Hellenic Cooperative Oncology Group (HeCOG)[J]. Ann Oncol, 2001, 12: 1231-1238. DOI: 10.1023/A:1012295131640
    [35]
    Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer[J]. N Engl J Med, 2002, 346: 85-91. DOI: 10.1056/NEJMoa003034
    [36]
    Hanna N, Bunn PA Jr, Langer C, et al. Randomized phase Ⅲ trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer[J]. J Clin Oncol, 2006, 24: 2038-2043. DOI: 10.1200/JCO.2005.04.8595
    [37]
    McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage Ⅲ and stage Ⅳ ovarian cancer[J]. N Engl J Med, 1996, 334: 1-6. DOI: 10.1056/NEJM199601043340101
    [38]
    Piccart MJ, Bertelsen K, James K, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results[J]. J Natl Cancer Inst, 2000, 92: 699-708. DOI: 10.1093/jnci/92.9.699
    [39]
    Ozols RF, Bundy BN, Greer BE, et al. Phase Ⅲ trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage Ⅲ ovarian cancer: a Gynecologic Oncology Group study[J]. J Clin Oncol, 2003, 21: 3194-3200. DOI: 10.1200/JCO.2003.02.153
    [40]
    du Bois A, Lück HJ, Meier W, et al. A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer[J]. J Natl Cancer Inst, 2003, 95: 1320-1329. DOI: 10.1093/jnci/djg036
    [41]
    Chan JK, Tian C, Fleming GF, et al. The potential benefit of 6 vs. 3 cycles of chemotherapy in subsets of women with early-stage high-risk epithelial ovarian cancer: an explora-tory analysis of a Gynecologic Oncology Group study[J]. Gynecol Oncol, 2010, 116: 301-306. DOI: 10.1016/j.ygyno.2009.10.073
    [42]
    Trimbos JB, Vergote I, Bolis G, et al. European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer-Adjuvant ChemoTherapy in Ovarian Neoplasm trial[J]. J Natl Cancer Inst, 2003, 95: 113-125. DOI: 10.1093/jnci/95.2.113
    [43]
    Vasey PA, Jayson GC, Gordon A, et al. Phase Ⅲ randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma[J]. J Natl Cancer Inst, 2004, 96: 1682-1691. DOI: 10.1093/jnci/djh323
    [44]
    Pignata S, Scambia G, Ferrandina G, et al. Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase Ⅲ trial[J]. J Clin Oncol, 2011, 29: 3628-3635. DOI: 10.1200/JCO.2010.33.8566
    [45]
    Burger RA, Brady MF, Bookman MA, et al. Incorpo-ration of bevacizumab in the primary treatment of ovarian cancer[J]. N Engl J Med, 2011, 365: 2473-2483. DOI: 10.1056/NEJMoa1104390
    [46]
    Oza AM, Cook AD, Pfisterer J, et al. Standard chemo-therapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a phase 3 randomised trial[J]. Lancet Oncol, 2015, 16: 928-936. DOI: 10.1016/S1470-2045(15)00086-8
    [47]
    Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial[J]. Lancet, 2009, 374: 1331-1338. DOI: 10.1016/S0140-6736(09)61157-0
    [48]
    Chan JK, Brady MF, Penson RT, et al. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer[J]. N Engl J Med, 2016, 374: 738-748. DOI: 10.1056/NEJMoa1505067
    [49]
    Clamp AR, James EC, McNeish IA, et al. Weekly dose-dense chemotherapy in first-line epithelial ovarian, fallopian tube, or primary peritoneal carcinoma treatment (ICON8): primary progression free survival analysis results from a GCIG phase 3 randomised controlled trial[J]. Lancet, 2019, 394: 2084-2095. DOI: 10.1016/S0140-6736(19)32259-7
    [50]
    Pignata S, Scambia G, Katsaros D, et al. Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial[J]. Lancet Oncol, 2014, 15: 396-405. DOI: 10.1016/S1470-2045(14)70049-X
    [51]
    Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage Ⅲ ovarian cancer[J]. N Engl J Med, 1996, 335: 1950-1955. DOI: 10.1056/NEJM199612263352603
    [52]
    Markman M, Bundy BN, Alberts DS, et al. Phase Ⅲ trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage Ⅲ ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group[J]. J Clin Oncol, 2001, 19: 1001-1007. DOI: 10.1200/JCO.2001.19.4.1001
    [53]
    Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer[J]. N Engl J Med, 2006, 354: 34-43. DOI: 10.1056/NEJMoa052985
    [54]
    Walker JL, Brady MF, Wenzel L, et al. Randomized Trial of Intravenous Versus Intraperitoneal Chemotherapy Plus Bevacizumab in Advanced Ovarian Carcinoma: An NRG Oncology/Gynecologic Oncology Group Study[J]. J Clin Oncol, 2019, 37: 1380-1390. DOI: 10.1200/JCO.18.01568
    [55]
    van Driel WJ, Koole SN, Sikorska K, et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer[J]. N Engl J Med, 2018, 378: 230-240. DOI: 10.1056/NEJMoa1708618
    [56]
    International Collaborative Ovarian Neoplasm Group. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial[J]. Lancet, 2002, 360: 505-515. DOI: 10.1016/S0140-6736(02)09738-6
    [57]
    Pignata S, Breda E, Scambia G, et al. A phase Ⅱ study of weekly carboplatin and paclitaxel as first-line treatment of elderly patients with advanced ovarian cancer. A Multicentre Italian Trial in Ovarian cancer (MITO-5) study[J]. Crit Rev Oncol Hematol, 2008, 66: 229-236. DOI: 10.1016/j.critrevonc.2007.12.005
    [58]
    von Gruenigen VE, Huang HQ, Beumer JH, et al. Chemotherapy completion in elderly women with ovarian, primary peritoneal or fallopian tube cancer - An NRG oncology/Gynecologic Oncology Group study[J]. Gynecol Oncol, 2017, 144: 459-467. DOI: 10.1016/j.ygyno.2016.11.033
    [59]
    Falandry C, Rousseau F, Mouret-Reynier MA, et al. Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer: A GINECO/GCIG Randomized Clinical Trial[J]. JAMA Oncol, 2021, 7: 853-861. DOI: 10.1001/jamaoncol.2021.0696
    [60]
    Pignata S, Scambia G, Bologna A, et al. Randomized Controlled Trial Testing the Efficacy of Platinum-Free Interval Prolongation in Advanced Ovarian Cancer: The MITO-8, MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG Study[J]. J Clin Oncol, 2017, 35: 3347-3353. DOI: 10.1200/JCO.2017.73.4293
    [61]
    Raja FA, Counsell N, Colombo N, et al. Platinum versus platinum-combination chemotherapy in platinum-sensitive recurrent ovarian cancer: a meta-analysis using individual patient data[J]. Ann Oncol, 2013, 24: 3028-3034. DOI: 10.1093/annonc/mdt406
    [62]
    Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial[J]. Lancet, 2003, 361: 2099-2106.
    [63]
    Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG[J]. J Clin Oncol, 2006, 24: 4699-4707. DOI: 10.1200/JCO.2006.06.0913
    [64]
    Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al. Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse[J]. J Clin Oncol, 2010, 28: 3323-3329. DOI: 10.1200/JCO.2009.25.7519
    [65]
    Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase Ⅲ trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer[J]. J Clin Oncol, 2012, 30: 2039-2045. DOI: 10.1200/JCO.2012.42.0505
    [66]
    Coleman RL, Brady MF, Herzog TJ, et al. Bevacizumab and paclitaxel-carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2017, 18: 779-791. DOI: 10.1016/S1470-2045(17)30279-6
    [67]
    Pfisterer J, Shannon CM, Baumann K, et al. Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2020, 21: 699-709. DOI: 10.1016/S1470-2045(20)30142-X
    [68]
    Strauss HG, Henze A, Teichmann A, et al. Phase Ⅱ trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer[J]. Gynecol Oncol, 2007, 104: 612-616. DOI: 10.1016/j.ygyno.2006.09.023
    [69]
    Kushner DM, Connor JP, Sanchez F, et al. Weekly docetaxel and carboplatin for recurrent ovarian and peritoneal cancer: a phase Ⅱ trial[J]. Gynecol Oncol, 2007, 105: 358-364. DOI: 10.1016/j.ygyno.2006.12.018
    [70]
    Rose PG. Gemcitabine reverses platinum resistance in platinum-resistant ovarian and peritoneal carcinoma[J]. Int J Gynecol Cancer, 2005, 15: 18-22. DOI: 10.1136/ijgc-00009577-200505001-00004
    [71]
    Dieras V, Bougnoux P, Petit T, et al. Multicentre phase Ⅱ study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients[J]. Ann Oncol, 2002, 13: 258-266. DOI: 10.1093/annonc/mdf018
    [72]
    Chollet P, Bensmaïne MA, Brienza S, et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer[J]. Ann Oncol, 1996, 7: 1065-1070. DOI: 10.1093/oxfordjournals.annonc.a010500
    [73]
    Piccart MJ, Green JA, Lacave AJ, et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase Ⅱ study of the European Organization for Research and Treatment of Cancer Gynecology Group[J]. J Clin Oncol, 2000, 18: 1193-1202. DOI: 10.1200/JCO.2000.18.6.1193
    [74]
    Ge L, Li N, Yuan GW, et al. Nedaplatin and paclitaxel compared with carboplatin and paclitaxel for patients with platinum-sensitive recurrent ovarian cancer[J]. Am J Cancer Res, 2018, 8: 1074-1082. http://www.zhangqiaokeyan.com/academic-journal-foreign-pmc_american-journal-cancer-research_thesis/040004261840.html
    [75]
    Gietema JA, Veldhuis GJ, Guchelaar HJ, et al. Phase Ⅱ and pharmacokinetic study of lobaplatin in patients with relapsed ovarian cancer[J]. Br J Cancer, 1995, 71: 1302-1307. DOI: 10.1038/bjc.1995.252
    [76]
    李瑛花. 洛铂联合多西他赛治疗复发性卵巢癌的疗效[J]. 中南大学学报(医学版), 2014, 39: 1131-1136. DOI: 10.11817/j.issn.1672-7347.2014.11.005
    [77]
    Silasi DA, Illuzzi JL, Kelly MG, et al. Carcinosarcoma of the ovary[J]. Int J Gynecol Cancer, 2008, 18: 22-29. DOI: 10.1111/j.1525-1438.2007.00948.x
    [78]
    Dandamudi RK, Aslam S, Walji N, et al. Chemotherapy for Uterine Carcinosarcoma with Carboplatin, Ifosfamide and Mesna[J]. Anticancer Res, 2015, 35: 4841-4847. http://www.researchgate.net/profile/Dr_Ravi_Dandamudi/publication/280910092_Chemotherapy_for_Uterine_Carcinosarcoma_with_Carboplatin_Ifosfamide_and_Mesna/links/570fff9908ae74cb7d9eff2c.pdf
    [79]
    Sugiyama T, Okamoto A, Enomoto T, et al. Randomized Phase Ⅲ Trial of Irinotecan Plus Cisplatin Compared With Paclitaxel Plus Carboplatin As First-Line Chemotherapy for Ovarian Clear Cell Carcinoma: JGOG3017/GCIG Trial[J]. J Clin Oncol, 2016, 34: 2881-2887. DOI: 10.1200/JCO.2016.66.9010
    [80]
    Lee HJ, Kim HS, Park NH, et al. Feasibility of Oxaliplatin, Leucovorin, and 5-Fluorouracil (FOLFOX-4) Chemotherapy in Heavily Pretreated Patients with Recurrent Epithelial Ovarian Cancer[J]. Cancer Res Treat, 2013, 45: 40-47. DOI: 10.4143/crt.2013.45.1.40
    [81]
    Emmanouilides C, Sfakiotaki G, Androulakis N, et al. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with meta-static colorectal cancer: a multicenter phase Ⅱ study[J]. BMC Cancer, 2007, 7: 91. DOI: 10.1186/1471-2407-7-91
    [82]
    Gore M, Hackshaw A, Brady WE, et al. An international, phase Ⅲ randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor[J]. Gynecol Oncol, 2019, 153: 541-548. DOI: 10.1016/j.ygyno.2019.03.256
    [83]
    Powell MA, Filiaci VL, Hensley ML, et al. A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage Ⅰ-Ⅳ, persistent or recurrent carcino-sarcoma of the uterus or ovary: An NRG Oncology trial[J]. J Clin Oncol, 2019, 37: 5500. DOI: 10.1200/JCO.2019.37.15_suppl.5500
    [84]
    Rutledge TL, Gold MA, McMeekin DS, et al. Carcinosar-coma of the ovary-a case series[J]. Gynecol Oncol, 2006, 100: 128-132. DOI: 10.1016/j.ygyno.2005.07.119
    [85]
    Sundar S, Symonds RP, Decatris MP, et al. Phase Ⅱ trial of Oxaliplatin and 5-Fluorouracil/Leucovorin combination in epithelial ovarian carcinoma relapsing within 2 years of platinum-based therapy[J]. Gynecol Oncol, 2004, 94: 502-508. DOI: 10.1016/j.ygyno.2004.04.020
    [86]
    Pectasides D, Pectasides M, Farmakis D, et al. Oxaliplatin plus high-dose leucovorin and 5-fluorouracil (FOLFOX 4) in platinum-resistant and taxane-pretreated ovarian cancer: a phase Ⅱ study[J]. Gynecol Oncol, 2004, 95: 165-172. DOI: 10.1016/j.ygyno.2004.06.029
    [87]
    Rosa DD, Awada A, Mano MS, et al. Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma[J]. Arch Gynecol Obstet, 2008, 278: 457-462. DOI: 10.1007/s00404-008-0592-9
    [88]
    Slayton RE, Park RC, Silverberg SG, et al. Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. A Gynecologic Oncology Group Study (a final report)[J]. Cancer, 1985, 56: 243-248. DOI: 10.1002/1097-0142(19850715)56:2<243::AID-CNCR2820560206>3.0.CO;2-T
    [89]
    Williams SD, Blessing JA, Moore DH, et al. Cisplatin, vinblastine, and bleomycin in advanced and recurrent ovarian germ-cell tumors. A trial of the Gynecologic Oncology Group[J]. Ann Intern Med, 1989, 111: 22-27. DOI: 10.7326/0003-4819-111-1-22
    [90]
    Gershenson DM, Morris M, Cangir A, et al. Treatment of malignant germ cell tumors of the ovary with bleomycin, etoposide, and cisplatin[J]. J Clin Oncol, 1990, 8: 715-720. DOI: 10.1200/JCO.1990.8.4.715
    [91]
    Williams S, Blessing JA, Liao SY, et al. Adjuvant therapy of ovarian germ cell tumors with cisplatin, etoposide, and bleomycin: a trial of the Gynecologic Oncology Group[J]. J Clin Oncol, 1994, 12: 701-706. DOI: 10.1200/JCO.1994.12.4.701
    [92]
    Williams SD, Kauderer J, Burnett AF, et al. Adjuvant therapy of completely resected dysgerminoma with carboplatin and etoposide: a trial of the Gynecologic Oncology Group[J]. Gynecol Oncol, 2004, 95: 496-499. DOI: 10.1016/j.ygyno.2004.07.044
    [93]
    Billmire DF, Cullen JW, Rescorla FJ, et al. Surveillance after initial surgery for pediatric and adolescent girls with stageⅠovarian germ cell tumors: report from the Children's Oncology Group[J]. J Clin Oncol, 2014, 32: 465-470. http://www.ncbi.nlm.nih.gov/pubmed/24395845
    [94]
    Kondagunta GV, Bacik J, Donadio A, et al. Combination of paclitaxel, ifosfamide, and cisplatin is an effective second-line therapy for patients with relapsed testicular germ cell tumors[J]. J Clin Oncol, 2005, 23: 6549-6555. DOI: 10.1200/JCO.2005.19.638
    [95]
    Hinton S, Catalano PJ, Einhorn LH, et al. Cisplatin, etoposide and either bleomycin or ifosfamide in the treatment of disseminated germ cell tumors: final analysis of an intergroup trial[J]. Cancer, 2003, 97: 1869-1875. DOI: 10.1002/cncr.11271
    [96]
    Einhorn LH, Williams SD, Chamness A, et al. High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors[J]. N Engl J Med, 2007, 357: 340-348. DOI: 10.1056/NEJMoa067749
    [97]
    Loehrer PJ Sr, Gonin R, Nichols CR, et al. Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor[J]. J Clin Oncol, 1998, 16: 2500-2504. DOI: 10.1200/JCO.1998.16.7.2500
    [98]
    Nichols CR, Roth BJ, Loehrer PJ, et al. Salvage chemotherapy for recurrent germ cell cancer[J]. Semin Oncol, 1994, 21: 102-108. http://europepmc.org/abstract/MED/7992061
    [99]
    Xiao H, Mazumdar M, Bajorin DF, et al. Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin[J]. J Clin Oncol, 1997, 15: 2553-2558. DOI: 10.1200/JCO.1997.15.7.2553
    [100]
    Schneider DT, Calaminus G, Harms D, et al. Ovarian sex cord-stromal tumors in children and adolescents[J]. J Clin Oncol, 2003, 21: 2357-2363. DOI: 10.1200/JCO.2003.05.038
    [101]
    Gurumurthy M, Bryant A, Shanbhag S. Effectiveness of different treatment modalities for the management of adult-onset granulosa cell tumours of the ovary (primary and recurrent)[J]. Cochrane Database Syst Rev, 2014, 2014: CD006912. http://www.ncbi.nlm.nih.gov/pubmed/24753008
    [102]
    Park JY, Jin KL, Kim DY, et al. Surgical staging and adjuvant chemotherapy in the management of patients with adult granulosa cell tumors of the ovary[J]. Gynecol Oncol, 2012, 125: 80-86. DOI: 10.1016/j.ygyno.2011.12.442
    [103]
    Homesley HD, Bundy BN, Hurteau JA, et al. Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: A Gynecologic Oncology Group study[J]. Gynecol Oncol, 1999, 72: 131-137. DOI: 10.1006/gyno.1998.5304
    [104]
    Pautier P, Gutierrez-Bonnaire M, Rey A, et al. Combina-tion of bleomycin, etoposide, and cisplatin for the treatment of advanced ovarian granulosa cell tumors[J]. Int J Gynecol Cancer, 2008, 18: 446-452. DOI: 10.1111/j.1525-1438.2007.01049.x
    [105]
    Brown J, Shvartsman HS, Deavers MT, et al. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors[J]. Gynecol Oncol, 2005, 97: 489-496. DOI: 10.1016/j.ygyno.2005.01.011
    [106]
    Hogberg T, Signorelli M, de Oliveira CF, et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-results from two randomised studies[J]. Eur J Cancer, 2010, 46: 2422-2431. DOI: 10.1016/j.ejca.2010.06.002
    [107]
    Randall ME, Filiaci VL, Muss H, et al. Randomized phase Ⅲ trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study[J]. J Clin Oncol, 2006, 24: 36-44. DOI: 10.1200/JCO.2004.00.7617
    [108]
    de Boer SM, Powell ME, Mileshkin L, et al. Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial[J]. Lancet Oncol, 2019, 20: 1273-1285. DOI: 10.1016/S1470-2045(19)30395-X
    [109]
    Matei D, Filiaci V, Randall ME, et al. Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer[J]. N Engl J Med, 2019, 380: 2317-2326. DOI: 10.1056/NEJMoa1813181
    [110]
    Thigpen JT, Brady MF, Homesley HD, et al. Phase Ⅲ trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study[J]. J Clin Oncol, 2004, 22: 3902-3908. DOI: 10.1200/JCO.2004.02.088
    [111]
    Fleming GF, Brunetto VL, Cella D, et al. Phase Ⅲ trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study[J]. J Clin Oncol, 2004, 22: 2159-2166. DOI: 10.1200/JCO.2004.07.184
    [112]
    Miller DS, Filiaci VL, Mannel RS, et al. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase Ⅲ Trial (NRG Oncology/GOG0209)[J]. J Clin Oncol, 2020, 38: 3841-3850. DOI: 10.1200/JCO.20.01076
    [113]
    Rose PG, Ali S, Moslemi-Kebria M, et al. Paclitaxel, Carboplatin, and Bevacizumab in Advanced and Recurrent Endometrial Carcinoma[J]. Int J Gynecol Cancer, 2017, 27: 452-458. DOI: 10.1097/IGC.0000000000000891
    [114]
    Miyamoto M, Takano M, Kuwahara M, et al. Efficacy of combination chemotherapy using irinotecan and nedaplatin for patients with recurrent and refractory endometrial carcinomas: preliminary analysis and literature review[J]. Cancer Chemother Pharmacol, 2018, 81: 111-117. DOI: 10.1007/s00280-017-3454-y
    [115]
    Fracasso PM, Blessing JA, Molpus KL, et al. Phase Ⅱ study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study[J]. Gynecol Oncol, 2006, 103: 523-526. DOI: 10.1016/j.ygyno.2006.03.043
    [116]
    Fader AN, Roque DM, Siegel E, et al. Randomized Phase Ⅱ Trial of Carboplatin-Paclitaxel Compared with Carboplatin-Paclitaxel-Trastuzumab in Advanced (Stage Ⅲ-Ⅳ) or Recurrent Uterine Serous Carcinomas that Overexpress Her2/Neu (NCT01367002): Updated Overall Survival Analysis[J]. Clin Cancer Res, 2020, 26: 3928-3935. DOI: 10.1158/1078-0432.CCR-20-0953
    [117]
    Sutton G, Brunetto VL, Kilgore L, et al. A phase Ⅲ trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study[J]. Gynecol Oncol, 2000, 79: 147-153. DOI: 10.1006/gyno.2000.6001
    [118]
    Homesley HD, Filiaci V, Markman M, et al. Phase Ⅲ trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study[J]. J Clin Oncol, 2007, 25: 526-531. DOI: 10.1200/JCO.2006.06.4907
    [119]
    Lan C, Huang X, Cao X, et al. Adjuvant docetaxel and carboplatin chemotherapy administered alone or with radiotherapy in a "sandwich" protocol in patients with advanced endometrial cancer: a single-institution experience[J]. Expert Opin Pharmacother, 2013, 14: 535-542. DOI: 10.1517/14656566.2013.778243
    [120]
    Nomura H, Aoki D, Takahashi F, et al. Randomized phaseⅡ study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041)[J]. Ann Oncol, 2011, 22: 636-642. DOI: 10.1093/annonc/mdq401
    [121]
    Montana GS, Thomas GM, Moore DH, et al. Preoperative chemo-radiation for carcinoma of the vulva with N2/N3 nodes: a gynecologic oncology group study[J]. Int J Radiat Oncol Biol Phys, 2000, 48: 1007-1013. DOI: 10.1016/S0360-3016(00)00762-8
    [122]
    Moore DH, Ali S, Koh WJ, et al. A phase Ⅱ trial of radia-tion therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study[J]. Gynecol Oncol, 2012, 124: 529-533. DOI: 10.1016/j.ygyno.2011.11.003
    [123]
    Ngan HYS, Seckl MJ, Berkowitz RS, et al. Update on the diagnosis and management of gestational trophoblastic disease[J]. Int J Gynaecol Obstet, 2018, 143: 79-85. DOI: 10.1002/ijgo.12615
    [124]
    Li J, Yue H, Wang X, et al. Chemotherapy for gestational trophoblastic neoplasia patients with a FIGO score of 12 or greater: A multistudy analysis[J]. Eur J Obstet Gynecol Reprod Biol, 2019, 238: 164-169. DOI: 10.1016/j.ejogrb.2019.05.023
    [125]
    Alifrangis C, Agarwal R, Short D, et al. EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis[J]. J Clin Oncol, 2013, 31: 280-286. http://hwmaint.jco.ascopubs.org/cgi/reprint/31/2/280.pdf
    [126]
    Mao Y, Wan X, Lv W, et al. Relapsed or refractory gesta-tional trophoblastic neoplasia treated with the etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EP-EMA) regimen[J]. Int J Gynaecol Obstet, 2007, 98: 44-47. DOI: 10.1016/j.ijgo.2007.03.037
    [127]
    Xiang Y, Sun Z, Wan X, et al. EMA/EP chemotherapy for chemorefractory gestational trophoblastic tumor[J]. J Reprod Med, 2004, 49: 443-446. http://europepmc.org/abstract/MED/15283051
    [128]
    Cyriac S, Rajendranath R, Sridevi V, et al. Etoposide, cisplatin-etoposide, methotrexate, actinomycin-D as primary treatment for management of very-high-risk gestational trophoblastic neoplasia[J]. Int J Gynecol Obstet, 2011, 115: 37-39. DOI: 10.1016/j.ijgo.2011.04.017
    [129]
    Wang J, Short D, Sebire NJ, et al. Salvage chemotherapy of relapsed or high-risk gestational trophoblastic neoplasia (GTN) with paclitaxel/cisplatin alternating with paclitaxel/etoposide (TP/TE)[J]. Ann Oncol, 2008, 19: 1578-1583. DOI: 10.1093/annonc/mdn181
    [130]
    Alazzam M, Tidy J, Osborne R, et al. Chemotherapy for resistant or recurrent gestational trophoblastic neoplasia[J]. Cochrane Database Syst Rev, 2012(12): CD008891. http://www.researchgate.net/profile/Theresa_Lawrie/publication/233909071_Chemotherapy_for_Resistant_or_Recurrent_Gestational_Trophoblastic_Neoplasia/links/5b86f8ac299bf1d5a731127d/Chemotherapy-for-Resistant-or-Recurrent-Gestational-Trophoblastic-Neoplasia.pdf
    [131]
    Oun R, Moussa YE, Wheate NJ. The side effects of platinum-based chemotherapy drugs: a review for chemists[J]. Dalton Trans, 2018, 47: 6645-6653. DOI: 10.1039/C8DT00838H
    [132]
    广东省药学会. 铂类药物临床应用与不良反应管理专家共识[J]. 今日药学, 2019, 29: 577-586. https://www.cnki.com.cn/Article/CJFDTOTAL-YAXU201909003.htm
    [133]
    Kamimura K, Matsumoto Y, Zhou Q, et al. Myelosuppression by chemotherapy in obese patients with gynecological cancers[J]. Cancer Chemother Pharmacol, 2016, 78: 633-641. DOI: 10.1007/s00280-016-3119-2
    [134]
    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hematopoietic growth factor (2021.V4)[EB/OL ].[2021-08-25]. https://www.nccn.org/profe-ssionals/physician_gls/pdf/growthfactors.pdf.
    [135]
    Keng MK, Sekeres MA. Febrile neutropenia in hema-tologic malignancies[J]. Curr Hematol Malig Rep, 2013, 8: 370-378. DOI: 10.1007/s11899-013-0171-4
    [136]
    Rose PG. Amifostine cytoprotection with chemotherapy for advanced ovarian carcinoma[J]. Semin Oncol, 1996, 23: 83-89. http://www.ncbi.nlm.nih.gov/pubmed/8783673
    [137]
    Rodgers GM, Gilreath JA. The Role of Intravenous Iron in the Treatment of Anemia Associated with Cancer and Chemotherapy[J]. Acta Haematol, 2019, 142: 13-20. DOI: 10.1159/000496967
    • Related Articles

  • Related Articles

    [1]MAO Mingyi, JIANG Fang, XIANG Yang. Current Status of Diagnosis and Treatment of High-risk Resistant and Recurrent Gestational Trophoblastic Neoplasia[J]. Medical Journal of Peking Union Medical College Hospital, 2025, 16(1): 157-162. DOI: 10.12290/xhyxzz.2024-0135
    [2]CHEN Chen, WU Ying, HUA Xian, LU Jinnan, LI Yi, ZHAO Chunhua, MIN Han. Influence of Host Factors on Drug Resistance of Helicobacter Pylori Infection[J]. Medical Journal of Peking Union Medical College Hospital, 2024, 15(5): 1091-1099. DOI: 10.12290/xhyxzz.2024-0011
    [3]SU Pengfei, YU Jianchun. Progress in the Research on the Role of Tumor-associated Macrophages in Drug-resistance and Treatment of Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(3): 480-486. DOI: 10.12290/xhyxzz.2021-0605
    [4]Gynecological Oncology Society of Chinese Medical Association. Clinical Practice Guidelines for Immune Checkpoint Inhibitor Therapy in Gynecological Tumors[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(6): 854-880. DOI: 10.12290/xhyxzz.2021-0683
    [5]Wei WANG, Ling-ya PAN. The Concept of Evidence-based Medicine Leads to Better Clinical Outcomes: Guidelines for Enhanced Recovery after Surgery in Gynecologic/ Oncology 2019 Update and Interpretation[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(6): 582-588. DOI: 10.3969/j.issn.1674-9081.2019.06.006
    [6]Lei LI, Yang XIANG. Reducing Surgical Injury is Always the Determinant Factor for Enhanced Recovery after Gynecological Oncology Surgery[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(6): 557-561. DOI: 10.3969/j.issn.1674-9081.2019.06.002
    [7]Ying-chun XU, Jing-jing HUANG, Meng XIAO, Xin-fei CHEN, Ya-ting NING, Xin FAN, Yang YANG, Jia-jia FENG, Li-kai LIN. Current Status of Clinical Infection of Candida Auris in China[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(5): 442-445. DOI: 10.3969/j.issn.1674-9081.2019.05.003
    [8]Ya-li LIU, Wen-juan ZHANG, Jie WANG, Sha YE, Ying ZHAO, He WANG, Hong-tao DOU, Li-na GUO, Yao WANG, Hong-li SUN, Wen-jing LIU, Xiao-jiang ZHANG, Xiu-li XIE, Ying YUAN, Qi-wen YANG, Ying-chun XU. In Vitro Drug Sensitivity of Ureaplasma Species and Mycoplasma Hominis and the Mechanism of Resistance to Quinolones: A Single-center Retrospective Study[J]. Medical Journal of Peking Union Medical College Hospital, 2019, 10(3): 249-256. DOI: 10.3969/j.issn.1674-9081.2019.03.011
    [9]Yun LONG, Qing-hua GUO, Da-wei LIU, Xiao-jiang ZHANG, Lian-yan SONG, Huai-wu HE. Risk Factors and Clinical Outcomes of Pan-drug Resistant Acinetobacter baumannii Bacteremia[J]. Medical Journal of Peking Union Medical College Hospital, 2015, 6(4): 260-266. DOI: 10.3969/j.issn.1674-9081.2015.04.005
    [10]Ya-gang ZUO, Hong-wei WANG, Jia-bi WANG. Dual-wavelength Laser with 595 nm and 1064 nm Combination for Resistant Port-wine Stains[J]. Medical Journal of Peking Union Medical College Hospital, 2012, 3(4): 386-389. DOI: 10.3969/j.issn.1674-9081.2012.04.005

  • Cited by

    Periodical cited type(0)

    Other cited types(1)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (1684) PDF downloads (269) Cited by(1)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close